JP7376532B2 - てんかんを処置する方法 - Google Patents
てんかんを処置する方法 Download PDFInfo
- Publication number
- JP7376532B2 JP7376532B2 JP2021093227A JP2021093227A JP7376532B2 JP 7376532 B2 JP7376532 B2 JP 7376532B2 JP 2021093227 A JP2021093227 A JP 2021093227A JP 2021093227 A JP2021093227 A JP 2021093227A JP 7376532 B2 JP7376532 B2 JP 7376532B2
- Authority
- JP
- Japan
- Prior art keywords
- alprazolam
- seizures
- inhalation device
- seizure
- inhalation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010015037 epilepsy Diseases 0.000 title claims description 47
- 206010010904 Convulsion Diseases 0.000 claims description 162
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims description 153
- 229960004538 alprazolam Drugs 0.000 claims description 150
- 239000000443 aerosol Substances 0.000 claims description 56
- 229940079593 drug Drugs 0.000 claims description 42
- 239000003814 drug Substances 0.000 claims description 42
- 238000011282 treatment Methods 0.000 claims description 30
- 239000002245 particle Substances 0.000 claims description 27
- 238000010438 heat treatment Methods 0.000 claims description 14
- 239000000758 substrate Substances 0.000 claims description 14
- 238000001704 evaporation Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 208000024891 symptom Diseases 0.000 claims description 12
- 230000008020 evaporation Effects 0.000 claims description 11
- 208000034308 Grand mal convulsion Diseases 0.000 claims description 8
- 206010071082 Juvenile myoclonic epilepsy Diseases 0.000 claims description 7
- 208000034287 idiopathic generalized susceptibility to 7 epilepsy Diseases 0.000 claims description 7
- 230000002035 prolonged effect Effects 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 208000028311 absence seizure Diseases 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 230000006735 deficit Effects 0.000 claims description 4
- 208000028329 epileptic seizure Diseases 0.000 claims description 4
- 208000028316 focal seizure Diseases 0.000 claims description 4
- 208000028326 generalized seizure Diseases 0.000 claims description 4
- 208000033001 Complex partial seizures Diseases 0.000 claims description 3
- 206010040703 Simple partial seizures Diseases 0.000 claims description 3
- 206010043994 Tonic convulsion Diseases 0.000 claims description 3
- 208000005809 status epilepticus Diseases 0.000 claims description 3
- 206010003628 Atonic seizures Diseases 0.000 claims description 2
- 206010053398 Clonic convulsion Diseases 0.000 claims description 2
- 230000019771 cognition Effects 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 238000009834 vaporization Methods 0.000 claims 1
- 230000008016 vaporization Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 description 49
- 206010039897 Sedation Diseases 0.000 description 19
- 230000036280 sedation Effects 0.000 description 19
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 18
- 206010003791 Aura Diseases 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- 230000036470 plasma concentration Effects 0.000 description 17
- 206010061334 Partial seizures Diseases 0.000 description 13
- 230000001154 acute effect Effects 0.000 description 11
- 206010034972 Photosensitivity reaction Diseases 0.000 description 10
- 230000001787 epileptiform Effects 0.000 description 10
- 230000036211 photosensitivity Effects 0.000 description 10
- 230000000007 visual effect Effects 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 229940049706 benzodiazepine Drugs 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 230000002411 adverse Effects 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 230000003556 anti-epileptic effect Effects 0.000 description 7
- 150000001557 benzodiazepines Chemical class 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 201000003040 photosensitive epilepsy Diseases 0.000 description 6
- 230000000306 recurrent effect Effects 0.000 description 6
- 201000005070 reflex epilepsy Diseases 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 206010041349 Somnolence Diseases 0.000 description 5
- 239000001961 anticonvulsive agent Substances 0.000 description 5
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 208000037048 Prodromal Symptoms Diseases 0.000 description 4
- 238000013528 artificial neural network Methods 0.000 description 4
- 229960003529 diazepam Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 208000032140 Sleepiness Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002996 emotional effect Effects 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 230000003400 hallucinatory effect Effects 0.000 description 3
- 231100000016 inhalation toxicity Toxicity 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 3
- 230000003238 somatosensory effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000011287 therapeutic dose Methods 0.000 description 3
- 239000010409 thin film Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
- 208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000037158 Partial Epilepsies Diseases 0.000 description 2
- 206010048727 Postictal state Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940097831 alprazolam 0.5 mg Drugs 0.000 description 2
- 230000000573 anti-seizure effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000007177 brain activity Effects 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000001037 epileptic effect Effects 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000001339 gustatory effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000010984 neurological examination Methods 0.000 description 2
- 231100001079 no serious adverse effect Toxicity 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000006479 redox reaction Methods 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- GUJAGMICFDYKNR-UHFFFAOYSA-N 1,4-benzodiazepine Chemical compound N1C=CN=CC2=CC=CC=C12 GUJAGMICFDYKNR-UHFFFAOYSA-N 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 206010012177 Deja vu Diseases 0.000 description 1
- 208000003078 Generalized Epilepsy Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 206010052437 Nasal discomfort Diseases 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 208000012761 aggressive behavior Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940086882 alprazolam 1 mg Drugs 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229940074202 diastat Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001709 ictal effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 230000001343 mnemonic effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000000337 motor cortex Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 231100000191 repeated dose toxicity Toxicity 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 229940125706 skeletal muscle relaxant agent Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940074158 xanax Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Description
この特許文書の開示の一部は、特許権保護の対象である材料を含む。著作権者は、いずれかによる、特許商標庁への特許出願又は記録であると認められる特許文書又は特許開示の複写に対しては異議を唱えないが、それ以外のあらゆる全ての著作権の権利を保有する。
Claims (23)
- 発作の予測可能な進展を有する患者におけるてんかんを治療するための吸入装置であって、前記治療が、焦点(部分)発作及び全般発作から選択される進行中の発作の停止であり、前記患者はてんかん重積状態を有さず、
ここで前記装置が、アルプラゾラム組成物を加熱して蒸気を形成させるための第一のエレメントと;該蒸気を放冷し、それにより凝縮エアロゾルを提供する第二のエレメントと;該エアロゾルの吸入を可能にする第三のエレメントと、を含み、
前記アルプラゾラム組成物は、基板にコーティングされたアルプラゾラムの被膜であり、前記被膜は0.1~10μmの厚さを有し、390±50℃の温度に加熱され、1秒以内にアルプラゾラムの実質的に完全な蒸発を生じる基材上にコーティングされており、
ここで前記蒸発は、4~50L/分の間の蒸発化合物上の気流速度を伴うものであって、
ここでアルプラゾラムの気化はアルプラゾラムエアロゾル粒子を生成し、前記アルプラゾラムエアロゾル粒子の少なくとも80重量%が5ミクロン未満のサイズを有し、
ここで前記装置が呼吸作動式であり、前記患者がマウスピースを通して1回吸気すれば薬物を送達し、吸気ごとに0.5~2mgのアルプラゾラムを提供し、これにより治療効果が吸入後2分までに最大又はほぼ最大となる、
吸入装置。 - 前記進行中の発作が、長期の焦点(部分)発作又は全般発作から選択される、請求項1に記載の吸入装置。
- 前記全般発作が、欠神発作、ミオクロニー発作、間代発作、強直発作、強直間代発作、及び脱力発作から選択される、請求項1に記載の吸入装置。
- 前記全般発作が、欠神発作、ミオクロニー発作及び強直間代発作から選択される、請求項1に記載の吸入装置。
- 前記全般発作が、欠神発作、ミオクロニー発作及び強直間代発作から選択される、請求項2に記載の吸入装置。
- 前記長期の焦点発作が、複雑部分発作又は単純部分発作である、請求項2に記載の吸入装置。
- 前記焦点発作が、全般強直間代発作へと発展する、請求項1に記載の吸入装置。
- 前記全般発作が、二次性全般発作及び若年ミオクロニーてんかんに関連する発作から選択される、請求項1に記載の吸入装置。
- 前記全般発作が、二次性全般発作及び若年ミオクロニーてんかんに関連する発作から選択される、請求項2に記載の吸入装置。
- 前記進行中の発作が、長期の焦点部分発作、二次性全般発作、又は欠神発作、ミオクロニー発作及び強直間代発作から選択される全般発作である、請求項1に記載の吸入装置。
- 前記アルプラゾラムが、てんかん発作の1つ又は複数の症状の開始後に、前記患者によって自己投与される、請求項1に記載の吸入装置。
- 前記アルプラゾラムが、意識/認識の障害を有さない長期の焦点発作の間に、前記患者によって自己投与される、請求項2に記載の吸入装置。
- 前記アルプラゾラムが、介護者の支援を借りて、意識の障害を有する患者に投与される、請求項1に記載の吸入装置。
- 前記アルプラゾラムが、1~2mgの用量で投与される、請求項2に記載の吸入装置。
- 前記エアロゾルがアルプラゾラムエアロゾル粒子を含み、前記粒子の少なくとも80%が5μm未満のサイズを有し、かつ、前記粒子の少なくとも50%が2μm未満のサイズを有する、請求項1に記載の吸入装置。
- 携帯式で単回投与単回使用の吸入装置である、請求項1に記載の吸入装置。
- 前記加熱が、発熱化学反応によって生成される、請求項1に記載の吸入装置。
- 前記アルプラゾラムの血漿Tmaxが、吸入後5分未満である、請求項1に記載の吸入装置。
- 前記アルプラゾラムの血漿Tmaxが、吸入後5分未満である、請求項2に記載の吸入装置。
- 前記アルプラゾラムが、吸気ごとに1~2mgの用量で投与され、生物学的利用能が、静脈内投与されたアルプラゾラムで実現した場合の90~110%又はそれ以上である、請求項1に記載の吸入装置。
- 前記アルプラゾラムが、吸気ごとに1~2mgの用量で投与される、請求項1に記載の吸入装置。
- 前記アルプラゾラムは、いずれの他の共同作用も必要とすることなく、1回の吸気で投与される、請求項1に記載の吸入装置。
- 前記アルプラゾラムは、一回の通常の呼吸で投与される、請求項1に記載の吸入装置。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662432353P | 2016-12-09 | 2016-12-09 | |
US62/432,353 | 2016-12-09 | ||
US201762485281P | 2017-04-13 | 2017-04-13 | |
US62/485,281 | 2017-04-13 | ||
JP2019531043A JP7379154B2 (ja) | 2016-12-09 | 2017-12-08 | てんかんを処置する方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019531043A Division JP7379154B2 (ja) | 2016-12-09 | 2017-12-08 | てんかんを処置する方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021154135A JP2021154135A (ja) | 2021-10-07 |
JP7376532B2 true JP7376532B2 (ja) | 2023-11-08 |
Family
ID=62492165
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019531043A Active JP7379154B2 (ja) | 2016-12-09 | 2017-12-08 | てんかんを処置する方法 |
JP2021093227A Active JP7376532B2 (ja) | 2016-12-09 | 2021-06-02 | てんかんを処置する方法 |
JP2023075804A Pending JP2023118696A (ja) | 2016-12-09 | 2023-05-01 | てんかんを処置する方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019531043A Active JP7379154B2 (ja) | 2016-12-09 | 2017-12-08 | てんかんを処置する方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023075804A Pending JP2023118696A (ja) | 2016-12-09 | 2023-05-01 | てんかんを処置する方法 |
Country Status (17)
Country | Link |
---|---|
US (3) | US11241383B2 (ja) |
EP (2) | EP3551189B1 (ja) |
JP (3) | JP7379154B2 (ja) |
KR (3) | KR20230066655A (ja) |
CN (2) | CN116172985A (ja) |
AU (3) | AU2017370747A1 (ja) |
CA (1) | CA3046385C (ja) |
DK (1) | DK3551189T3 (ja) |
FI (1) | FI3551189T3 (ja) |
HR (1) | HRP20240106T1 (ja) |
IL (1) | IL267199A (ja) |
LT (1) | LT3551189T (ja) |
MX (2) | MX2019006745A (ja) |
PT (1) | PT3551189T (ja) |
RS (1) | RS65112B1 (ja) |
SI (1) | SI3551189T1 (ja) |
WO (1) | WO2018107045A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008112661A2 (en) | 2007-03-09 | 2008-09-18 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
US20120048963A1 (en) | 2010-08-26 | 2012-03-01 | Alexza Pharmaceuticals, Inc. | Heat Units Using a Solid Fuel Capable of Undergoing an Exothermic Metal Oxidation-Reduction Reaction Propagated without an Igniter |
SI3268072T1 (sl) | 2015-03-11 | 2024-03-29 | Alexza Pharmaceuticals, Inc. | Uporaba antistatičnih materialov v dovodu zraka za proces toplotne kondenzacije aerosolov |
PT3551189T (pt) | 2016-12-09 | 2024-01-22 | Alexza Pharmaceuticals Inc | Alprazolam para utilização no tratamento da epilepsia |
RU2765175C1 (ru) * | 2018-06-14 | 2022-01-26 | Филип Моррис Продактс С.А. | Устройство, генерирующее аэрозоль, с плоским нагревателем |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004531555A (ja) | 2001-05-24 | 2004-10-14 | アレックザ モレキュラー デリヴァリー コーポレイション | 所定の吸入ルートによるアルプラゾラム、エスタゾラム、ミダゾラムまたはトリアゾラムの送出 |
JP2005530765A (ja) | 2002-05-07 | 2005-10-13 | ネクター セラピューティクス | 乾燥粉末吸入器のためのカプセル及びそれを製造及び使用する方法 |
JP2008530134A (ja) | 2005-02-15 | 2008-08-07 | エラン ファーマ インターナショナル リミテッド | ナノ粒子ベンゾジアゼピンのエアロゾル製剤および注射用製剤 |
US20100181387A1 (en) | 2009-12-01 | 2010-07-22 | Zaffaroni Alejandro C | Aerosol delivery system and uses thereof |
JP2010526822A (ja) | 2007-05-07 | 2010-08-05 | クエスター ファーマシューティカルズ,インク. | ベンゾジアゼピン類の経鼻投与 |
JP2012180378A (ja) | 2000-09-19 | 2012-09-20 | Civitas Therapeutics Inc | 中枢神経系の障害の処置における肺送達 |
US20130156823A1 (en) | 2011-12-20 | 2013-06-20 | MAP Pharmacauticals, Inc. | Excipient-free Aerosol Formulation |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3987052A (en) | 1969-03-17 | 1976-10-19 | The Upjohn Company | 6-Phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines |
AU2001284158B2 (en) * | 2000-08-18 | 2004-03-25 | Norton Healthcare, Ltd. | Spray device |
US7498019B2 (en) | 2001-05-24 | 2009-03-03 | Alexza Pharmaceuticals, Inc. | Delivery of compounds for the treatment of headache through an inhalation route |
US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
US6737042B2 (en) | 2001-05-24 | 2004-05-18 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US7585493B2 (en) | 2001-05-24 | 2009-09-08 | Alexza Pharmaceuticals, Inc. | Thin-film drug delivery article and method of use |
US7645442B2 (en) | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
US7078016B2 (en) | 2001-11-21 | 2006-07-18 | Alexza Pharmaceuticals, Inc. | Delivery of caffeine through an inhalation route |
US6805853B2 (en) | 2001-11-09 | 2004-10-19 | Alexza Molecular Delivery Corporation | Delivery of diazepam through an inhalation route |
US20080038363A1 (en) | 2001-05-24 | 2008-02-14 | Zaffaroni Alejandro C | Aerosol delivery system and uses thereof |
US6759029B2 (en) | 2001-05-24 | 2004-07-06 | Alexza Molecular Delivery Corporation | Delivery of rizatriptan and zolmitriptan through an inhalation route |
US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
WO2002094244A2 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of benzodiazepines through an inhalation route |
US20030118512A1 (en) | 2001-10-30 | 2003-06-26 | Shen William W. | Volatilization of a drug from an inclusion complex |
WO2003045484A2 (en) | 2001-11-21 | 2003-06-05 | Alexza Molecular Delivery Corporation | Open-celled substrates for drug delivery |
AU2002361742A1 (en) | 2001-12-18 | 2003-06-30 | Alexza Molecular Delivery Corporation | Parental analgesic formulations comprising fentanyl and a cannabinoid receptor agonist |
EP1503744A1 (en) | 2002-05-13 | 2005-02-09 | Alexza Molecular Delivery Corporation | Delivery of drug amines through an inhalation route |
US20060193788A1 (en) | 2002-11-26 | 2006-08-31 | Hale Ron L | Acute treatment of headache with phenothiazine antipsychotics |
US20040105818A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
CN1717237A (zh) | 2002-11-26 | 2006-01-04 | 艾利斯达分子传输公司 | 洛沙平和阿莫沙平在制备治疗疼痛的药物中的应用 |
NZ540208A (en) | 2002-11-26 | 2007-09-28 | Alexza Pharmaceuticals Inc | Treatment of headache with antipsychotics delivered by inhalation |
US7550133B2 (en) | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
US7913688B2 (en) | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
ATE520935T1 (de) | 2003-05-21 | 2011-09-15 | Alexza Pharmaceuticals Inc | Verwendung einer schicht aus festem brennstoff, verfahren zum erstellen einer solchen schicht und zugehörige heizvorrichtung |
US20050037506A1 (en) | 2003-08-04 | 2005-02-17 | Alexza Molecular Delivery Corporation | Methods of determining film thicknesses for an aerosol delivery article |
AU2004264344B2 (en) | 2003-08-04 | 2011-02-17 | Alexza Pharmaceuticals, Inc. | Substrates for drug delivery device and methods of preparing and use |
EP1703932A1 (en) | 2003-12-15 | 2006-09-27 | Alexza Molecular Delivery Corporation | Treatment of breakthrough pain by drug aerosol inhalation |
WO2005059804A2 (en) | 2003-12-16 | 2005-06-30 | Alexza Pharmaceuticals, Inc. | Methods for monitoring severity of panic attacks and other rapidly evolving medical events in real-time |
US7402777B2 (en) | 2004-05-20 | 2008-07-22 | Alexza Pharmaceuticals, Inc. | Stable initiator compositions and igniters |
US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
AU2004322756B2 (en) | 2004-08-12 | 2011-04-14 | Alexza Pharmaceuticals, Inc. | Aerosol drug delivery device incorporating percussively activated heat packages |
US20060032496A1 (en) | 2004-08-12 | 2006-02-16 | Alexza Molecular Delivery Corporation | Inhalation actuated percussive ignition system |
US20100006092A1 (en) | 2004-08-12 | 2010-01-14 | Alexza Pharmaceuticals, Inc. | Aerosol Drug Delivery Device Incorporating Percussively Activated Heat Packages |
US20060120962A1 (en) | 2004-10-12 | 2006-06-08 | Rabinowitz Joshua D | Cardiac safe, rapid medication delivery |
JP5334588B2 (ja) * | 2005-11-28 | 2013-11-06 | マリナス ファーマシューティカルズ | ガナキソロン製剤、およびその作製方法、およびその使用 |
US7494344B2 (en) | 2005-12-29 | 2009-02-24 | Molex Incorporated | Heating element connector assembly with press-fit terminals |
WO2008080170A1 (en) | 2006-12-22 | 2008-07-03 | Alexza Pharmaceuticals, Inc. | Mixed drug aerosol compositiions |
US7513781B2 (en) | 2006-12-27 | 2009-04-07 | Molex Incorporated | Heating element connector assembly with insert molded strips |
WO2008112661A2 (en) | 2007-03-09 | 2008-09-18 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
US20080306285A1 (en) | 2007-04-27 | 2008-12-11 | Alexza Pharmaceuticals, Inc. | Heat-Labile Prodrugs |
WO2009089550A1 (en) | 2008-01-11 | 2009-07-16 | Alexza Pharmaceuticals, Inc. | Metal coordination complexes of volatile drugs |
CA2724483C (en) * | 2008-05-16 | 2018-01-02 | Arbor Vita Corporation | Psd-95 inhibitor for the treatment of epilepsy |
US20100068155A1 (en) | 2008-09-16 | 2010-03-18 | Alexza Pharmaceuticals, Inc. | Reactant Formulations and Methods for Controlled Heating |
US7834295B2 (en) | 2008-09-16 | 2010-11-16 | Alexza Pharmaceuticals, Inc. | Printable igniters |
US20100065052A1 (en) | 2008-09-16 | 2010-03-18 | Alexza Pharmaceuticals, Inc. | Heating Units |
US20100300433A1 (en) | 2009-05-28 | 2010-12-02 | Alexza Pharmaceuticals, Inc. | Substrates for Enhancing Purity or Yield of Compounds Forming a Condensation Aerosol |
US20120048963A1 (en) | 2010-08-26 | 2012-03-01 | Alexza Pharmaceuticals, Inc. | Heat Units Using a Solid Fuel Capable of Undergoing an Exothermic Metal Oxidation-Reduction Reaction Propagated without an Igniter |
WO2012075286A2 (en) * | 2010-12-01 | 2012-06-07 | The Regents Of The University Of California | Intrapulmonary benzodiazepine for the treatment and prevention of seizures |
AU2011335415B2 (en) * | 2010-12-02 | 2016-05-19 | Ucb Pharma Gmbh | Once daily formulation of lacosamide |
CN107737100A (zh) * | 2011-06-14 | 2018-02-27 | 哈尔生物药投资有限责任公司 | 苯二氮卓组合物的投与 |
CA3061122C (en) | 2013-07-11 | 2023-10-17 | Alexza Pharmaceuticals, Inc. | Nicotine salt with meta-salicylic acid |
SI3268072T1 (sl) | 2015-03-11 | 2024-03-29 | Alexza Pharmaceuticals, Inc. | Uporaba antistatičnih materialov v dovodu zraka za proces toplotne kondenzacije aerosolov |
PT3551189T (pt) | 2016-12-09 | 2024-01-22 | Alexza Pharmaceuticals Inc | Alprazolam para utilização no tratamento da epilepsia |
-
2017
- 2017-12-08 PT PT178786042T patent/PT3551189T/pt unknown
- 2017-12-08 RS RS20240089A patent/RS65112B1/sr unknown
- 2017-12-08 EP EP17878604.2A patent/EP3551189B1/en active Active
- 2017-12-08 CN CN202310415295.8A patent/CN116172985A/zh active Pending
- 2017-12-08 SI SI201731475T patent/SI3551189T1/sl unknown
- 2017-12-08 HR HRP20240106TT patent/HRP20240106T1/hr unknown
- 2017-12-08 FI FIEP17878604.2T patent/FI3551189T3/fi active
- 2017-12-08 DK DK17878604.2T patent/DK3551189T3/da active
- 2017-12-08 KR KR1020237015165A patent/KR20230066655A/ko not_active Application Discontinuation
- 2017-12-08 US US16/469,143 patent/US11241383B2/en active Active
- 2017-12-08 CN CN201780086216.6A patent/CN110267662A/zh active Pending
- 2017-12-08 WO PCT/US2017/065347 patent/WO2018107045A1/en active Application Filing
- 2017-12-08 LT LTEPPCT/US2017/065347T patent/LT3551189T/lt unknown
- 2017-12-08 CA CA3046385A patent/CA3046385C/en active Active
- 2017-12-08 EP EP23200086.9A patent/EP4272827A3/en active Pending
- 2017-12-08 KR KR1020197019402A patent/KR20190104531A/ko not_active IP Right Cessation
- 2017-12-08 JP JP2019531043A patent/JP7379154B2/ja active Active
- 2017-12-08 KR KR1020227041634A patent/KR20220164620A/ko active Application Filing
- 2017-12-08 AU AU2017370747A patent/AU2017370747A1/en not_active Abandoned
- 2017-12-08 MX MX2019006745A patent/MX2019006745A/es unknown
-
2019
- 2019-06-07 MX MX2022008775A patent/MX2022008775A/es unknown
- 2019-06-10 IL IL267199A patent/IL267199A/en unknown
-
2021
- 2021-04-28 AU AU2021202621A patent/AU2021202621B2/en active Active
- 2021-04-30 US US17/244,963 patent/US11717479B2/en active Active
- 2021-06-02 JP JP2021093227A patent/JP7376532B2/ja active Active
-
2022
- 2022-04-14 US US17/721,183 patent/US20220241191A1/en active Pending
- 2022-12-13 AU AU2022287583A patent/AU2022287583A1/en active Pending
-
2023
- 2023-05-01 JP JP2023075804A patent/JP2023118696A/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012180378A (ja) | 2000-09-19 | 2012-09-20 | Civitas Therapeutics Inc | 中枢神経系の障害の処置における肺送達 |
JP2004531555A (ja) | 2001-05-24 | 2004-10-14 | アレックザ モレキュラー デリヴァリー コーポレイション | 所定の吸入ルートによるアルプラゾラム、エスタゾラム、ミダゾラムまたはトリアゾラムの送出 |
JP2005530765A (ja) | 2002-05-07 | 2005-10-13 | ネクター セラピューティクス | 乾燥粉末吸入器のためのカプセル及びそれを製造及び使用する方法 |
JP2008530134A (ja) | 2005-02-15 | 2008-08-07 | エラン ファーマ インターナショナル リミテッド | ナノ粒子ベンゾジアゼピンのエアロゾル製剤および注射用製剤 |
JP2010526822A (ja) | 2007-05-07 | 2010-08-05 | クエスター ファーマシューティカルズ,インク. | ベンゾジアゼピン類の経鼻投与 |
US20100181387A1 (en) | 2009-12-01 | 2010-07-22 | Zaffaroni Alejandro C | Aerosol delivery system and uses thereof |
US20130156823A1 (en) | 2011-12-20 | 2013-06-20 | MAP Pharmacauticals, Inc. | Excipient-free Aerosol Formulation |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7376532B2 (ja) | てんかんを処置する方法 | |
Schenberg | Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development | |
RU2728689C2 (ru) | Способы, устройства и системы для легочной доставки активных средств | |
Li et al. | A comparison of intranasal dexmedetomidine for sedation in children administered either by atomiser or by drops | |
US7981401B2 (en) | Diuretic aerosols and methods of making and using them | |
EP2931291B1 (en) | Xenon treatment as an adjunct to psychotherapy for psychiatric disorders | |
Onischuk et al. | Generation, inhalation delivery and anti-hypertensive effect of nisoldipine nanoaerosol | |
Gangurde et al. | Lamotrigine lipid nanoparticles for effective treatment of epilepsy: a focus on brain targeting via nasal route | |
Lexmond et al. | Challenging the two-minute tidal breathing challenge test | |
Shahi et al. | A technology overview on advanced drug administration devices for effective nose-to-brain delivery | |
NZ795347A (en) | Method of treating epilepsy | |
Shrewsbury et al. | Drug delivery via the upper nasal space: A novel route for anesthesiologists, intensivists and emergency department physicians | |
Ashton | Emerging treatment options for spasticity in multiple sclerosis–clinical utility of cannabinoids | |
Milgrom et al. | Behavioral side effects of medications used to treat asthma and allergic rhinitis | |
US11400113B2 (en) | Dissolved C60 and method of producing dissolved C60 | |
US20220323491A1 (en) | Dissolved c60 and method of producing dissolved c60 | |
US20220233436A1 (en) | Method of using nebulized alcohol for analgesia | |
Chartier et al. | Baclofen-Induced Neurotoxicity | |
RU2593016C2 (ru) | Способ лечения артериальной гипертензии путем ингаляционного введения аэрозоля гипотензивного препарата | |
WO2020102334A1 (en) | Aromatherapy compositions for improving cognitive function | |
JP2012513475A (ja) | 薬物療法学養生法において感覚的な条件付け手がかり(sensoryconditioningcues)を付け加える方法 | |
Chapman | Aerosol therapy in Canada: what are the standards? | |
De La Harpe | A comparison of the efficacy and safety of intranasal sufentanil/midazolam and ketamine/midazolam for sedation and analgesia in a paediatric population undergoing multiple dental extractions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210624 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210624 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220323 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220329 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220629 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220929 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230524 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230728 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230926 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231026 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7376532 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |